Clinical trials: Frontotemporal Degeneration
Huntington's Disease (HD)
Biology-Driven Cognitive Profiling in Huntington's Disease
Huntington's disease (HD) is a genetic, progressive neurodegenerative disorder characterized by early and widespread brain changes that can begin more than a decade before the onset of unequivocal motor signs.
- Trial name
- NCT07503743
- Where
- Spain
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Mild Cognitive Impairment, Dementia
COMPARATIVE EFFECTIVENESS OF MCI and DEMENTIA TREATMENTS IN A COMMUNITY-BASED DEMENTIA PRACTICE
This retrospective study is a more extensive, confirmatory analysis of the cognitive and functional outcomes initially seen in 2 groups of MCI/dementia patients in Springfield, MA and compares specialized dementia care and a…
- Conditions
- Mild Cognitive Impairment, Dementia, Hypoxia, Hyperhomocysteinemia
- Trial name
- NCT02860338
- Volunteers
- 900 people
- Sponsor
- Clionsky Neuro Systems Inc.
Alzheimer Disease, Physical Activity
Is Tau Protein Linked to Mobility Function?
This project will provide new data to address an important question linking Alzheimer's disease neuropathology to physical disability.
- Trial name
- SYNERGY (NCT03430648)
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Wake Forest University Health Sciences
Frontotemporal Dementia
A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2)
A Phase 2 open label study evaluating the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of AL001 in participants with a Granulin mutation or C9orf72 mutation causative of frontotemporal dementia.
- Trial name
- NCT03987295
- Testing
- AL001
- Where
- 12 sites in United States, Canada and 4 more
- Volunteers
- 33 people
- Sponsor
- Alector Inc.
Dementia
Far Infrared Radiation Treatment of Dementia and Other Mental Illness
This trial is a preliminary study to determine the use of far infrared radiation for the treatment of dementia and other mental sickness.
- Trial name
- NCT00574054
- Testing
- Far Infrared
- Where
- Canada
- Volunteers
- 4 people
- Sponsor
- GAAD Medical Research Institute Inc.
Alzheimer Disease, Frontotemporal Degeneration (FTD)
PST for Care Partners of Adults With Alzheimer's and Alzheimer'S-related Dementia
Caregivers of individuals with Alzheimer's disease and related dementia rarely get the preparation or training they need to manage their caregiving responsibilities and to successfully balance their own self-care and their…
- Conditions
- Alzheimer Disease, Frontotemporal Degeneration (FTD), Lewy Body Dementia (LBD), Vascular Contributions to Cognitive Impairment and Dementia (VCID)
- Trial name
- NCT04748666
- Testing
- Problem Solving Training
- Where
- 3 sites in United States
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Aphasia Primary Progressive
Characterisation of Primary Progressives Aphasias
Primary progressive aphasias (PPA) represent a challenging group of degenerative language diseases that has led to growing interest in the scientific and medical community.
- Trial name
- CAPP (NCT02297035)
- Testing
- Behavioural testing, Brain imaging, Genetic screening
- Where
- France
- Volunteers
- 155 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Frontotemporal Lobar Degeneration
Effects of Tolcapone on Frontotemporal Dementia
This study will test the effects of a medication called tolcapone on cognitive, behavioral, and language problems seen in patients with frontotemporal dementia (FTD).
- Trial name
- NCT00604591
- Testing
- Tolcapone
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Columbia University
Frontal Lobe Dementia, Frontotemporal Lobe Dementia
Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia
The primary objective of the study is to determine whether memantine is effective in slowing the rate of behavioral decline in frontotemporal dementia.
- Conditions
- Frontal Lobe Dementia, Frontotemporal Lobe Dementia, Semantic Dementia
- Trial name
- NCT00545974
- Testing
- memantine
- Where
- 9 sites in United States
- Volunteers
- 81 people
- Sponsor
- University of California, San Francisco
Fronto-temporal Dementia, Fronto-temporal Lobar Dementia
Vortioxetine for the Treatment of Mood and Cognitive Symptoms in Frontotemporal Dementia
The goal of this clinical trial is to learn if vortioxetine improves mood symptoms and cognition in patients with early-stage behavioral variant Frontotemporal Dementia (bvFTD).
- Conditions
- Fronto-temporal Dementia, Fronto-temporal Lobar Dementia, Frontotemporal Degeneration, Frontotemporal Dementia (FTD)
- Trial name
- NCT06604520
- Testing
- Vortioxetine
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Dementia, Alzheimer Disease
Improving Prognostic Confidence in Neurodegenerative Diseases Causing Dementia Using Peripheral Biomarkers and Integrative Modeling
To develop a model to predict disease progression in a large cohort of patients across a variety of neurodegenerative diseases, including Mild Cognitive Impairment (MCI) and dementia due to any neurodegenerative disease…
- Conditions
- Dementia, Alzheimer Disease, Dementia With Lewy Bodies, Vascular Dementia
- Trial name
- CRND TorCA (NCT06529744)
- Where
- 4 sites in Canada
- Volunteers
- 500 people
- Sponsor
- University Health Network, Toronto
Alzheimer Disease
A Phase I [18F]THK-5351 Positron Emission Tomography Study in Healthy Subjects and Alzheimer's Disease
This is a study to evaluate biodistribution, pharmacokinetics and safety of [18F]THK-5351 positron emission computed tomography in Cognitively Healthy Subjects and Patients with Alzheimer's Disease.
- Trial name
- NCT03112096
- Testing
- [18F]THK-5351
- Where
- South Korea
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Asan Foundation
Frontotemporal Dementia
Epidemiological Study in FRONtoTemporal Dementia
An international, multicenter, epidemiological observational study aims to investigate the prevalence of genetic etiologies in patients diagnosed with FTD or clinically suspected for FTD.
- Trial name
- EFRONT (NCT05075187)
- Testing
- Genetic Screening
- Where
- 37 sites in Belgium, Germany and 5 more
- Volunteers
- 2,287 people, healthy volunteers welcome
- Sponsor
- CENTOGENE GmbH Rostock
Frontotemporal Dementia, Behavioral Variant
Intranasal Insulin in Frontotemporal Dementia (FTD)
This project will study intranasal (IN) insulin in Frontotemporal dementia (FTD) in 12 patients. Study Investigators aim to evaluate the feasibility of the EXAMINER cognitive battery as a cognitive outcome measure in FTD, the…
- Trial name
- NCT04115384
- Testing
- Novolin-R insulin
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- HealthPartners Institute
PSP, CBD
A Multi-Modal Remote Monitoring Platform for Frontotemporal Lobar Degeneration (FTLD) Syndromes
The primary objective of this study is to enroll an observational cohort of approximately 60 patients with PSP over the course of 24 months using a multicenter study design and to follow each of them for 12 months.
- Conditions
- PSP, CBD, Progressive Supranuclear Palsy, FTD
- Trial name
- NCT05956834
- Testing
- PAMSys, LEGSys
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Massachusetts General Hospital
Progressive Supranuclear Palsy (PSP)
Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear Palsy
This is a phase 1, multi-center, double-blind, placebo-controlled, multiple dose escalation study with NIO752 in progressive supranuclear palsy (PSP) participants.
- Trial name
- NCT04539041
- Testing
- antisense oligonucleotide
- Where
- 12 sites in United States, Canada and 2 more
- Volunteers
- 59 people
- Sponsor
- Novartis Pharmaceuticals
Alzheimer's Disease
Biodistribution of 11C-PIB PET in Alzheimer's Disease, Frontotemporal Dementia, and Cognitively Normal Elderly
Alzheimer's disease (AD) is characterized by neuritic plaques, neurofibrillary tangles, and neuronal cell loss. Amyloid plaques are believed to play an integral role in AD.
- Trial name
- 11C-PIB PET (NCT00811122)
- Testing
- 11C-PIB PET Scan, FDG-PET Scan
- Where
- United States
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- University of Utah
Frontotemporal Dementia
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia (FTD-GRN)
This is a Phase 1/2, multicenter, randomized, placebo-controlled, double-blind study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of DNL593 in two parts…
- Trial name
- NCT05262023
- Testing
- DNL593
- Where
- 26 sites in United States, Belgium and 10 more
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- Denali Therapeutics Inc.
Semantic Dementia
Veri-T: A Trial of Verdiperstat in Patients With svPPA Due to TDP-43 Pathology
The purpose of the study is to test the safety and tolerability of twice daily Verdiperstat in patients with semantic variant primary progressive aphasia (svPPA) due to frontotemporal lobar degeneration with TDP-43 pathology…
- Trial name
- Veri-T-001 (NCT05184569)
- Testing
- Verdiperstat
- Where
- 5 sites in United States
- Volunteers
- 64 people
- Sponsor
- Peter Ljubenkov, MD
Alzheimer Disease, Parkinson Disease
Research Study for Patients With Neurological Diseases Which Evaluates the Patient Experience of the MemorEM Device
Primary Objective: The primary objective of this pilot study is to gain voluntary feedback from patients with neurological diseases and their caregivers regarding their experiences using the MemorEM head device.
- Conditions
- Alzheimer Disease, Parkinson Disease, Frontotemporal Dementia, Cortico Basal Degeneration
- Trial name
- MemorEM (NCT07222605)
- Testing
- MemorEM
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- eQ8Health Corporation d/b/a CareONE Concierge